Daiichi Sankyo Subsidiary Submits NDA For SUN Y7017 In Japan
SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals. This drug was approved for use in the treatment of AD by the EMEA in 2002,
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.